Initial Evaluation Flashcards

1
Q

When doing imaging for a suspicious renal mass, which is best: abdominal CT/MRI or abdominopelvic CT/MRI? Is contrast preferred?

A

CONTRAST IS PREFERRED

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What are the ancillary procedures to be done only when there is clinical indication?

A

BONE SCAN
BRAIN MRI
CHEST CT
CORE NEEDLE BIOPSY

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

If renal biopsy is to be done, what needle is to be used?

When will you suspect urothelial carcinoma?

A

CORE NEEDLE because FNA is not sufficient

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

If urothelial carcinoma is suspected, what other procedures can you do for workup?

A

Ureteroscopy
Urine Cytology
Percutaneous Biopsy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

If metastatic disease is present or the patient cannot tolerate ureteroscopy for the initial workup, what can you do?

A

Percutaneous biopsy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

When will you consider genetic evaluation?

A

If the patient is 46 years old or younger

and positive family history

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Stage 1 (T1a) size and preferred primary treatment?

A

Tumor is 4cm or less

Partial nephrectomy is the preferred treatment

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Stage 1 (T1a) size and 3 other primary treatment?

A

Tumor is 4cm or less

Ablative techniques

AS for 2cm or less

Radical nephrectomy if partial nephrectomy is not feasible

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Stage 1 (T1b) size and primary treatment?

A

> 4-7cm

Partial nephrectomy
Radical nephrectomy
AS in selected patients

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

When is active surveillance indicated in renal masses?

A

2cm or less

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Stage 2 (T2a and T2b) sizes and primary treatment?

A

T2a >7-10 cm
T2b >10cm

Partial nephrectomy
or Radical nephrectomy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Stage 2 (T2a and T2b) adjuvant treatment?

A

May undergo clinical trial or surveillance

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Which structures are affected in T3a masses? (4)

A

T3a masses affect

Renal vein
Segmental branches
Pelvicalyceal system
Perirenal/renal sinus fat

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Which structure is affected in T3b masses?

A

IVC BELOW the diaphragm

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Which structure is affected in T3c masses?

A

IVC ABOVE the diaphragm

Wall of the vena cava

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

What structures is affected in T4 masses?

A

Beyond the Gerota’s

Adrenal gland

17
Q

Adjuvant treatment options for Stage II masses?

A

Clinical trial or surveillance

18
Q

Preferred adjuvant treatment option for Stage III clear cell histology masses.

A

Clinical trial

19
Q

Adjuvant option for non-clear cell histology patients?

Is surveillance an option in the adjuvant setting in clear cell histology Stage III masses?

A

Surveillance

20
Q

What category III adjuvant agent can you give Stage III patients with clear cell histology?

A

Sunitinib (Category 3)

21
Q

T1 N0 M0

A

STAGE I

22
Q

T2 N0 M0

A

STAGE II

23
Q

T1-T2 N1 M0

A

STAGE III

24
Q

T3, NX/N0/N1, M0

A

STAGE III

25
Q

T4, ANY N, M0

A

STAGE IV

26
Q

ANYT ANY N M1

A

STAGE IV

27
Q

G1

A

Nucleoli absent or inconspicuous and basophilic at 400x magnification

28
Q

G2

A

Nucleoli conspicuous and eosinophilic at 400x magnification, visible but not prominent at 100x magnification

29
Q

G3

A

Nucleoli conspicuous and eosinophilic at 100x magnification

30
Q

G4

A

Marked nuclear pleomorphism and/or multinucleate giant cells and/or rhabdoid and/or sarcomatoid differentiation